Your browser doesn't support javascript.
loading
Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations.
Christopoulos, Petros; Girard, Nicolas; Proto, Claudia; Soares, Marta; Lopez, Pilar Garrido; van der Wekken, Anthonie J; Popat, Sanjay; Diels, Joris; Schioppa, Claudio A; Sermon, Jan; Rahhali, Nora; Pick-Lauer, Corinna; Adamczyk, Agnieszka; Penton, James; Wislez, Marie.
Afiliación
  • Christopoulos P; Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, 69126 Heidelberg, Germany.
  • Girard N; German Center for Lung Research (DZL), 35392 Gießen, Germany.
  • Proto C; Institut Curie, Institut du Thorax Curie-Montsouris, 75005 Paris, France.
  • Soares M; Paris Saclay University, University of Versailles Saint-Quentin-en-Yvelines (UVSQ), 78000 Versailles, France.
  • Lopez PG; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
  • van der Wekken AJ; Instituto Português de Oncologia do Porto Francisco Gentil, 4200-072 Porto, Portugal.
  • Popat S; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
  • Diels J; University of Groningen, University Medical Centre Groningen, 9713 GZ Groningen, The Netherlands.
  • Schioppa CA; The Royal Marsden Hospital, London SW3 6JJ, UK.
  • Sermon J; The Institute of Cancer Research, London SW7 3RP, UK.
  • Rahhali N; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
  • Pick-Lauer C; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
  • Adamczyk A; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
  • Penton J; Janssen-Cilag Ltd., 92130 Issy-les-Moulineaux, France.
  • Wislez M; Janssen-Cilag GmbH, 41470 Neuss, Germany.
Cancers (Basel) ; 15(22)2023 Nov 08.
Article en En | MEDLINE | ID: mdl-38001589
Patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor gene (EGFR) Exon 20 insertions (Exon20ins) at the second line and beyond (2L+) have an unmet need for new treatment. Amivantamab, a bispecific EGFR- and MET-targeted antibody, demonstrated efficacy in this setting in the phase 1b, open-label CHRYSALIS trial (NCT02609776). The primary objective was to compare the efficacy of amivantamab to the choices made by real-world physicians (RWPC) using an external control cohort from the real-world evidence (RWE) chart review study, CATERPILLAR-RWE. Adjustment was conducted to address differences in prognostic variables between cohorts using inverse probability weighting (IPW) and covariate adjustments based on multivariable regression. In total, 114 patients from CHRYSALIS were compared for 55 lines of therapy from CATERPILLAR-RWE. Baseline characteristics were comparable between the amivantamab and IPW-weighted RWPC cohorts. For amivantamab versus RWPC using IPW adjustment, the response rate ratio for the overall response was 2.14 (p = 0.0181), and the progression-free survival (PFS), time-to-next-treatment (TTNT) and overall survival (OS) hazard ratios (HRs) were 0.42 (p < 0.0001), 0.47 (p = 0.0063) and 0.48 (p = 0.0207), respectively. These analyses provide evidence of clinical and statistical benefits across multiple outcomes and adjustment methods, of amivantamab in platinum pre-treated patients with advanced NSCLC harboring EGFR Exon20ins. These results confirm earlier comparisons versus pooled national registry data.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza